StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) fair value is $241/share without AD - Citi
March 21, 2019 8:28 AM
Citi analyst Robyn Karnauskas ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright
March 25, 2019 7:49 AM
Mizuho Securities Downgrades Biogen (BIIB) to Neutral
March 21, 2019 10:06 AM
Biogen (BIIB) PT Lowered to $275 at Cowen
March 21, 2019 9:20 AM
William Blair Downgrades Biogen (BIIB) to Market Perform
March 21, 2019 8:27 AM
Biogen (BIIB) PT Lowered to $250 at Baird on Alzheimer's Failure
March 21, 2019 8:20 AM
Guggenheim Sees Biogen (BIIB) Down 15-20% After 'Worst Fears Come True'
March 21, 2019 8:11 AM
Biogen (BIIB) option implied volatility low into discontinuing two Alzheimer's trials
March 21, 2019 7:55 AM
Biogen (BIIB) puts more active than calls into decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE
March 21, 2019 7:42 AM
Biogen (BIIB) option implied volatility low into decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE
March 21, 2019 7:38 AM
Biogen (BIIB) Resumes Trading, Down 25%
March 21, 2019 7:30 AM
Biogen (BIIB) to Resume Trading at 7:30 am ET
March 21, 2019 7:05 AM
Biogen (BIIB), Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in AD Due to Futility
March 21, 2019 7:01 AM
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
March 21, 2019 7:01 AM
